Rheumatoid arthritis
Conditions
Interventions
control: continue the present treatment
intervention: reduce the dosage of methotrexate by half every 3 months and discontinue
intervention: extend the interval of biologics to one and a half times e
Sponsors
Keio University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of rheumatoid arthritis treated with methotrexate and/or biologics who have sustained remission(DAS28<2.6) for 6 months
Exclusion criteria
Exclusion criteria: Patients who do not agree with the study Patients who are judged inappropriate in medical aspect by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of sustaining remission in patients who have continued the present therapy, tapered and discontinued methotrexate, and extended the interval of biologics 52 weeks after starting tapering. | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease activity, clinical characteristics, serological markers, rate of adverse events, FACS analysis, blood concentration of each drugs and antibodies against each drugs, serological concentration of cytokines and chemokines in patients who could successfully taper and discontinue anti-rheumatic drugs and who could not at the point anti-rheumatic drugs are started to be tapered, anti-rheumatic drugs are discontinued, and 52 weeks after anti-rheumatic drugs are started to be tapered. | — |
Countries
Japan
Contacts
Public ContactKunihiro Yamaoka
Keio University Hospital Division of Rheumatology
Outcome results
None listed